Meetings Archives • AMR.Solutions

FDA-NIAID-CDC: Developing drugs for gonorrhea, 23 Apr 21 workshop

Dear All, FDA, NIAID and CDC have announced a public workshop on development considerations of antimicrobial drugs for the treatment of gonorrhea. The workshop will cover both nonclinical (preclinical) and clinical trial design considerations: Animal models Clinical pharmacology considerations Trial design considerations for gonorrhea, such as enrollment strategies, choice of comparators and site of infection.

13 April 2021 No Comments

JPIAMR Diagnostics Call / James Bond’s occupational exposures

Dear All, A short one today! Please peruse both the funding opportunities and upcoming meetings just below my signature. Of special note: Building on the call in the recent biodefense-focused BAA from NIAID for diagnostic applications, JPIAMR is also looking for diagnostic applications (7 Mar deadline). Very interesting 2 Mar 2023 Duke-Margolis webinar entitled “Data Capture

7 February 2023 No Comments

Public meeting on the LPAD Pathway: Post-meeting thoughts (wonkish)

Long and wonkish note alert — please refresh your coffee before you start reading! Dear All: I was able to attend and speak at the 12 July 2019 Public Meeting organized by FDA on the LPAD (Limited Population Antibacterial and Antifungal Drug) pathway. The current draft guidance is here and the meeting agenda is found here. The meeting

22 July 2019 No Comments

Hot meetings x 3! FDA Microbiome AdComm, Diagnostic devices, ASM-ESCMID developer meeting

Dear All, I think it’s worth a newsletter to call your attention to several upcoming meetings. In addition to the 30 Aug CDC-FDA webinar on “Drug Development Considerations for the Prevention of Healthcare-Associated Infections” and PACCARB’s 12-13 Sep 2022 pandemic wargaming event, we have these 3 meetings. The first two just now hit my radar and

26 August 2022 No Comments

Job Opportunity with Duke-Margolis! / Phage workshop! / The Martian!

Dear All, I have many times previously shared webinars from the excellent policy team at Duke-Margolis Center for Health Policy. Excitingly if you are in search of that type of role, they are now looking for a Policy Analyst who would be located in either Washington, DC or Durham, NC. Here is the verbatim job summary from

30 September 2022 No Comments

WAAW events: Global voices, FT’s antibiotic dashboard, JPIAMR calls, FAO Action Plan!

Dear All, World Antimicrobial Awareness Week (WAAW) was such a mad scramble! So many events … just no way to attend everything. Some of the highlights in and around WAAW (not everything was precisely within the WAAW dates, thank goodness!) for me were: Andrew Jack and the team at FT (Financial Times) have released an

3 December 2021 No Comments

Meetings and more: Pandemic wargames! NIAID developer workshop! New stewardship prize!

Dear All, As suggested by the subject line, this newsletter is a bit of a mish-mash of time-critical news about meetings and opportunities! The main thing is to look closely at the funding and meeting summaries below my signature for NEW items. Here are a few highlights: Do you recall IDSA’s scary 2004 hypothetical scenario

11 May 2022 No Comments

UK Antibiotic Subscription Pilot: Updates from a webinar

Dear All (and with thanks to Kevin Outterson for co-authoring), We’ve written and talked before from various perspectives about the groundbreaking UK NHS England-, NHS Improvement-, and NICE-sponsored antibiotic subscription pilot project: 10 Feb 2021: Fabulous 5-minute video explainer on the economics of antibiotics by Andrew Jack of Financial Times Superb discussions of Push/Pull, the role

11 February 2021 No Comments

Jan-Feb meetings; CDC releases Healthcare Epidemiology RFP

Dear All: Happy New Year! I hope everyone was able to take a least a brief break over the holidays. Two things for today. First, there are two meetings in January and one in February that have just popped onto my radar. See the meetings calendar for a pair of Keystone Symposia on the microbiome,

2 January 2021 No Comments

FDA workshop: Insights on inhaled antifungals and antibacterials

Dear All (wonkish alert … coffee up!), FDA held a workshop on 25 Sep 2020 on development of inhaled antifungal (AF) therapies with a focus on (i) therapies for allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS), (ii) prophylaxis in lung transplantation, and (iii) adjunct therapy in invasive fungal lung infections (link to

18 October 2020 No Comments

AMR.Solutions

Meetings